Title:
Use of Allopurinol for hand-and-foot skin reaction medical treatment
Document Type and Number:
Japanese Patent JP6007101
Kind Code:
B2
Abstract:
Use of allopurinol or a pharmaceutically acceptable salt thereof for the treatment or prevention of Hand Foot Skin Reaction (HFSR) induced by Multitargeted Kinase (MKI) therapy. The allopurinol or its salt is administered topically to the affected areas, palms and soles, preferably in the form of a cream.
Inventors:
Rohdemer, Yolanda
Application Number:
JP2012507765A
Publication Date:
October 12, 2016
Filing Date:
April 29, 2010
Export Citation:
Assignee:
Novella Pharma Sociedad Limitada
International Classes:
A61K31/519; A61K9/107; A61P17/00
Foreign References:
| WO2007138103A1 |
Other References:
ROBERT,C. et al,Dermatologic symptoms associated with the multikinase inhibitor sorafenib,JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY,2009 (Feb.),vol.60,no.2,pp.299-305
LACOUTURE,M.E. et al,Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib,THE ONCOLOGIST,2008,vol.13,no.9,pp.1001-1011
ROSENBAUM,S.E. et al,Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib,SUPPORTIVE CARE IN CANCER,2008,vol.16,no.6,pp.557-566
BELDNER,M. et al,Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib,THE ONCOLOGIST,2007,vol.12,no.10,pp.1178-1182
YANG,C-H. et al,Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy,British of Journal of Dermatology,2008 ,vol.158, pp.592-596
ANDERSON,R. et al,Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction(HFSR) caused by the multikinase inhibitors(MKIs),THE ONCOLOGIST,2009(Mar.),vol.14,no.3,pp.291-302
WOOD,L.S. et al,Practical consideration in the management of hand-foot skin reaction caused by multikinase inhibitors, COMMUNITY ONCOLOGY,2010 (Jan.),vol. 7, no. 1,pp.23-29
LACOUTURE,M.E. et al,Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib,THE ONCOLOGIST,2008,vol.13,no.9,pp.1001-1011
ROSENBAUM,S.E. et al,Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib,SUPPORTIVE CARE IN CANCER,2008,vol.16,no.6,pp.557-566
BELDNER,M. et al,Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib,THE ONCOLOGIST,2007,vol.12,no.10,pp.1178-1182
YANG,C-H. et al,Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy,British of Journal of Dermatology,2008 ,vol.158, pp.592-596
ANDERSON,R. et al,Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction(HFSR) caused by the multikinase inhibitors(MKIs),THE ONCOLOGIST,2009(Mar.),vol.14,no.3,pp.291-302
WOOD,L.S. et al,Practical consideration in the management of hand-foot skin reaction caused by multikinase inhibitors, COMMUNITY ONCOLOGY,2010 (Jan.),vol. 7, no. 1,pp.23-29
Attorney, Agent or Firm:
Konno Akio
Minoru Inami
Takeyasu Ito
Keisei Tamura
Minoru Inami
Takeyasu Ito
Keisei Tamura